Pharmaceutical Contract Manufacturing Market (2nd Edition) | Industry Analysis | Market Size

Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

Lowest Price Guaranteed
From USD 3,499
Published
March 2018
Pages
520
View Count
2441
Order Now

Overview
Contents
Segmentation
Request Sample
Request Customization
Free Insights

Example Insights

Over 500 companies across the world are currently offering pharmaceutical contract manufacturing services. Service providers offer a variety of pharmaceutical services; these range from formulation services, stability studies / stability testing, method development / analytical development / process development, clinical trial material manufacturing, scale-up, registration batch manufacturing, commercial production and packaging and labelling service. It is worth highlighting that several CMOs offer end-to-end services across all scales of operations; examples of such players include (in alphabetical order) Aenova, Alcami® Pharma, AMRI, Catalent®, CMIC Group, CordenPharma, Dalton Pharma Services, Fresenius Kabi, Hovione, Recipharm, Siegfried and WuXi AppTec.
At present, the market is highly fragmented and is a mix of established companies (>200 employees, 52%), mid-sized companies (>50 employees, 26%) and small-sized companies (<50 employees, 21%) offering contract manufacturing services at various scales of operations. 46% of the companies are specifically providing FDF manufacturing services while 23% are specifically providing API manufacturing services. The remaining 31% of the companies offer both API and FDF contract manufacturing services.
Regulatory authorities play an active role in making pharmaceutical industry one of the most highly regulated industries across the world. We observed that 79% of the CMOs have received operational approval and certification from the USFDA. This is followed by the companies that have received operational approval from the European Medicines Agency (33%), World Health Organization (30%) and UK Medicines and Healthcare products Regulatory Agency (20%). In addition, several CMOs have sought / received operational approval and certification from the regulatory bodies in other regions such as Australia, Brazil, China, Canada, India and South Africa.
The current global contract pharmaceutical installed manufacturing capacity is estimated to be over 115 million liters. It is also worth mentioning that, amongst all the CMOs we evaluated, established CMOs contribute a significant proportion (78%) to the overall supply. Having said that, relatively small-sized or mid-sized companies are one of the key driving forces behind the heightened pace of pharmaceutical research and development. In addition, of the total installed capacity, over 75% of the total installed capacity is being used for both clinical and commercial production.
Amidst increasing competition in the outsourcing domain, CMOs are actively investigating and adopting several innovative tools and strategies in order to advance the development of drugs with higher success rates and improve the overall productivity. Examples of such strategies (in no specific order) include usage of big data analytics, green chemistry (such as solvent reduction and replacement, refining a chemical route and biocatalysis to optimize API synthesis), continuous process manufacturing system, digital medicines, 3D printed pill technologies, robotics and automation instruments for packaging, adoption of improved waste management and environment friendly strategies along with the integration of cybersecurity solutions.
Driven by increasing global demand and rapid approval of small molecule drugs by the USFDA, we expect the overall contract manufacturing market in the pharmaceutical domain to grow at an annualized rate of 4.8% between 2018 and 2028. The growth is likely to be higher in emerging markets of Asia-Pacific and rest of the world.
In terms of type of API product (branded and generic), generic APIs hold the current major share of the market (84%) while the remaining share (16%) of the total outsourced API market is occupied by branded APIs. Within the contract FDF market, solid dose compounds (~50%) currently dominate the market followed by injectables (33%) and semi-solid / liquid compounds (17%). The future growth is likely to be driven by injectables dose manufacturing primarily due to increased focus on complex disease areas and the growing trend of self-administration.
In terms of type of FDF, the most popular type is primary packaging of tablets / capsules / blisters, which currently hold 26% of the total FDF contract manufacturing market. This is further followed by glass / plastic / dropper bottles (21%) and vials / cartridge (15%). Other packaging forms such as ampoules, ointments / gels / tubes and sachets / pouches / infusion bags also hold a considerable share of the current FDF contract manufacturing market.
North America currently holds the largest share (34.3%) in the overall contract manufacturing market and is anticipated to continue to grow at an annualized growth rate of 2.9%. This is followed by Asia-Pacific and Europe that account for 34.1% and 30.3% share of the overall contract manufacturing market, respectively. However, markets in Asia-Pacific are expected to grow at a significantly higher CAGR of 7.1%, owing to inherent advantages such as relatively low labor costs and less stringent regulatory constraints.

Overview

Trends related to manufacturing have changed completely in the last 10-12 years. Large pharma companies are rapidly expanding their offerings by acquiring smaller companies. At the same time, some players are transferring their R&D and manufacturing operations to smaller players, while themselves operating as virtual companies.

-President and CEO, US based mid-sized CMO

The present pipeline of pharmaceutical products is increasingly complex and requires specialized facilities, equipment and operational expertise. Small molecule drugs account for nearly 90% of the therapeutics in the pharmaceutical market. In fact, in 2017, FDA’s Center for Drug Evaluation and Research approved 34 small molecule drugs; this represents an annual growth of nearly 56%, signifying the growing importance of contract manufacturing in the overall pharmaceutical industry. The costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. The aforementioned constraints have led many of the smaller players in the industry and, at times, certain pharma giants as well, to outsource a significant part of their business operations to contract service providers. Third-party service providers are known to offer significant cost-benefits, access to larger production capacities and reductions in time-to-market.

Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. Since 2000, close to 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.

The current global CMO market is highly fragmented but characterized by multiple acquisitions and mergers as stakeholders strive to broaden their respective service portfolios. This has enabled several CMOs to start offering end-to-end services, ranging from drug development, including preliminary R&D, preclinical and clinical trials, to commercial scale production and regulatory filings.

Despite the fact that the pharmaceutical sector is amongst the most highly regulated industries, we expect the demand for core competencies to continue to drive sponsor companies to outsource various parts of their manufacturing operations. Amidst tough competition, the availability of advanced tools and technologies is an important differentiating factor and will grant a competitive edge to certain CMOs over other stakeholders in the industry. However, given the ongoing innovation in production technologies and the steadily evolving pipeline of small molecules, the pressure on the contract manufacturing industry is expected to increase in the coming years. This is likely to require CMOs to devise and implement different business strategies and models in order to cope with the evolving demand.

Scope of Report

The ‘Pharmaceutical Contract Manufacturing Market (2^nd Edition), 2018-2028’ report provides a comprehensive study on the current scenario of contract manufacturing services related to pharmaceutical products. The study features an in-depth analysis, highlighting the capabilities of a diverse set of pharmaceutical CMOs. Amongst other elements, the report features:

An overview of the current market landscape, featuring a comprehensive list of over 500 active CMOs, and detailed analysis of manufacturing service providers based on a number of parameters, such as geographical location of CMOs, type of business segments (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), type of FDFs manufactured (solids, liquids / semi-solids and injectables), scale of operation (pilot, clinical, and commercial), type of service(s) offered, specific location of manufacturing facilities (country-wise) and types of primary packaging forms being manufactured (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe). In addition, the report features a year-wise analysis of the number of CMOs that have been established over the past five decades, based on the year in which they were founded.
An analysis of the most active regions, based on the presence of contract manufacturers; the report contains schematic world map representations indicating the geographical location of key hubs with respect to contract manufacturing activity across the globe.
A detailed discussion of various guidelines laid down by major regulatory bodies in different countries. The report also includes a comprehensive assessment of over 500 CMOs, including details of operational approvals and certifications received by each firm. In addition, the report highlights the relative popularity of the key regulatory bodies across the globe based on the number of companies which comply to the guidelines laid down by each of these authorities. The report also features an insightful multi-dimensional bubble analysis, featuring a comparison of the current regulatory scenario in key geographies across the globe.
Elaborate profiles of key players that offer end-to-end services ranging from product design and discovery to final packaging. Each profile provides an overview of the company, its financial performance (if available), information on its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.
A case study comparing the key characteristics of large molecule and small molecule drugs, along with the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are currently offering contract manufacturing services for large molecules.
A comprehensive set of analyses on pharmaceutical contract manufacturing service providers featuring three schematic representations, which include [A] a heat map analysis featuring the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of headquarters, year of establishment and number of employees, [B] a geographical landscape analysis,highlighting those CMOs that have a significantly wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees and the type of business operation.
A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the industry. The analysis takes into consideration the actual capacities of small-sized, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. The study highlights the distribution of global capacity by scale of operation (clinical, commercial, both), regions (North America, Europe, Asia-Pacific, rest of the world) and specific countries within North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world.
A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution. It also offers a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
A review of emerging trends, including the increase in outsourcing activity in emerging markets, shift towards an integrated business model through expansions and consolidation, introduction of innovative technologies / continuous processing systems, use of big data and advanced analytics to improve the manufacturing process and adoption of cybersecurity solutions to protect confidential customer data. It also includes a detailed discussion on the various growth drivers, such as increasing demand for biologics, biosimilars, and highly potent and cytotoxic drugs.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the pharmaceutical contract manufacturing market over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2028. In addition, we have provided the likely distribution of the market based on [A] type of business segment (API and FDF), [B] regional evolution of the market covering North America (the US, Canada and Mexico), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, Australia and rest of Asia) and rest of the world, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large companies). To account for the uncertainties associated with the growth of pharmaceutical contract manufacturing market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. This enabled us to solicit inputs on upcoming opportunities and challenges that were considered to develop estimates for a more inclusive growth. The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following stakeholders:

Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea)
Thomas Früh (CEO, Bachem)
Piyush Desai (Director, Operations, Sovereign Pharma)
Claire Otjes (Assistant Manager, Marketing, Batavia Biosciences)
Dietmar Katinger (CEO, Polymun Scientific)
Birgit Schwab (Senior Manager, Strategic Marketing, Rentschler Biopharma)
Sebastian Schuck (Head, Business Development, WACKER Biotech)
Bhaskar Venepalli (President and CEO, CiVentiChem)
Roberto Margarita (Director, Business Development, CordenPharma)
Allison Vavala (Senior Manager, Business Development, Helsinn Group)
Kevin Daley (Director, Pharmaceuticals Marketing, Novasep)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high-level view on the likely evolution of pharmaceutical contract manufacturing market, in the short-mid and long term.

Chapter 3 is a general introduction to various type of manufacturers in the pharmaceutical market. It features a brief overview of the concept of contract manufacturing and a general discussion on the evolution of the contract services in the pharmaceutical industry. It also includes a detailed discussion on the need for outsourcing in this domain. Further, we have provided a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry, till date. We have also presented an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the market.

Chapter 4 provides a comprehensive view on the global landscape of pharmaceutical CMOs. It includes information related to over 500 CMOs that are currently active in the pharmaceutical industry. It features an in-depth market review, including regional distribution, analysis by company size and year of establishment, type of business segments, type of FDFs manufactured, scale of operation, type of service(s) offered, location of manufacturing facilities and different types of primary packaging forms being manufactured.

Chapter 5 featuresa detailed discussion on the guidelines laid down by major regulatory bodies across different countries. The report also includes an assessment of over 500 CMOs related to the operational approvals and certifications received from various regulatory bodies, along with a schematic world map representation, highlighting the relative popularity (in terms of the number of companies that are operating in compliance to the guidelines laid down by each regulatory authority) of the key regulatory bodies across the globe. In addition, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies across the globe.

Chapter 6 features detailed profiles of some of the key players that are active in the pharmaceutical contract manufacturing market and are acting as one-stop-shops. Each profile presents a brief overview of the company, its financial information (if available) , details related to its service(s) portfolio, manufacturing facilities and capabilities, recent developments (acquisitions / mergers, collaborations and expansions) and a comprehensive future outlook.

Chapter 7 is a case study comparing the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes. In addition, it provides an overview of the current biopharmaceutical contract manufacturing landscape, featuring a list of over 200 CMOs that are offering contract manufacturing services for large molecules / biologics.

Chapter 8 presents a collection of key insights derived from the study. It includes a heat map analysis, highlighting the number of integrated players based on the location of their headquarters, year of establishment and number of employees. The chapter also features a geographical landscape analysis, wherein pharmaceutical CMOs having a relatively wide geographical reach, are highlighted. For this analysis, we have also highlighted the geographical locations of the aforementioned companies on a world map. In addition, the chapter includes a schematic grid analysis, featuring the distribution of pharmaceutical CMOs based on location of their headquarters, number of employees and the type of business operations (API / FDF / both).

Chapter 9 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of pharmaceutical products. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small-sized, mid-sized, large and very large CMOs, distributed across their respective facilities. The results of this analysis were used to establish an accurate opinion on outsourcing capabilities of the CMOs across different geographies / regions and scales of operation (clinical, commercial and both). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 10 provides a comprehensive market forecast analysis, highlighting the future potential of pharmaceutical contract manufacturing till the year 2028. It features the likely distribution of the market based on [A] type of business segment (API and FDF), [B] region (North America, Europe, Asia-Pacific and rest of the world) and further distribution by major countries within the aforementioned regions, [C] type of API product (branded and generic) within the aforementioned regions, [D] type of FDFs manufactured (solids, liquids / semi-solids and injectables), [E] type of packaging forms (tablet / capsule / blister packing, ointment / gel / tube, vial, ampoule, sachet / pouch / bag, glass / plastic bottle and pre-filled syringe), [F] scale of API manufacturing (clinical, commercial, and both) and [G] size of manufacturers (small sized, mid-sized, large and very large-companies).

Chapter 11 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under a comprehensive SWOT framework. The chapter also highlights a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall pharmaceutical industry.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters. It also provides a brief overview of some of the upcoming future trends, which, we believe, are likely to influence the growth of pharmaceutical CMOs in the foreseen future.

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Scott Goldstein (Associate Director, Drug Product Manufacturing, Ajinomoto Althea), Thomas Früh (CEO, Bachem), Piyush Desai (Director, Operations, Sovereign Pharma), Claire Otjes (Assistant Manager, Marketing, Batavia Biosciences), Dietmar Katinger (CEO, Polymun Scientific), Birgit Schwab (Senior Manager, Strategic Marketing, Rentschler Biopharma), Sebastian Schuck (Head, Business Development, WACKER Biotech), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Senior Manager, Business Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers in the Contract Manufacturing Industry
3.3. An Overview of the Pharmaceutical Contract Manufacturing Industry
3.4. Evolution of the Pharmaceutical Contract Manufacturing Industry
3.4.1. Traditional CMOs
3.4.2. Modern CMOs
3.5. The Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnership
3.6.2. Integrated End-to-End Business Model
3.6.3. Strategic Long-Term Alliance
3.6.4. Flexible Short-Term Partnership
3.6.5. Software Service Providers
3.7. Services Offered by CMOs
3.8. Selecting a CMO Partner
3.9. Risks and Challenges in Contract Manufacturing Industry

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Pharmaceutical CMOs: List of Industry Players
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Company Size
4.2.4. Distribution by Type of Business Segment
4.2.5. Distribution by Type of FDF Offered
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Type of Service Offering
4.2.8. Distribution by Location of Manufacturing Facilities
4.2.9. Distribution by Type of Primary Packaging Form Offered

5. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. Regulatory Guidelines in North America
5.2.1. The US Scenario
5.2.2. Canadian Scenario
5.3. Regulatory Guidelines in Europe
5.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
5.4.1. Chinese Scenario
5.4.2. Indian Scenario
5.4.3. Japanese Scenario
5.4.4. South Korean Scenario
5.4.5. Australian Scenario
5.4.6. Brazilian Scenario
5.5. Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
5.6. Bubble Analysis: Regional Regulatory Summary

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Importance of One-Stop-Shops
6.3. Company Profiles of One-Stop-Shops

6.4. Players in North America
6.4.1. Albany Molecular Research (AMRI)
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Financial Information
6.4.1.4. Manufacturing Capabilities and Facilities
6.4.1.5. Recent Developments
6.4.1.6. Future Outlook

6.4.2. Catalent Pharma Solutions
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Financial Information
6.4.2.4. Manufacturing Capabilities and Facilities
6.4.2.5. Recent Developments
6.4.2.6. Future Outlook

6.4.3. DPT Laboratories
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments
6.4.3.5. Future Outlook

6.4.4. Thermo Fisher Scientific (Through Acquisition of Patheon)
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Financial Information
6.4.4.4. Manufacturing Capabilities and Facilities
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook

6.5. Players in Europe
6.5.1. Aenova Group
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio
6.5.1.3. Financial Information
6.5.1.4. Manufacturing Capabilities and Facilities
6.5.1.5. Recent Developments
6.5.1.6. Future Outlook

6.5.2. Almac Group
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.5.2.3. Recent Developments
6.5.2.4. Future Outlook

6.5.3. CordenPharma
6.5.3.1. Company Overview
6.5.3.2. Service Portfolio
6.5.3.3. Manufacturing Capabilities and Facilities
6.5.3.4. Recent Developments
6.5.3.5. Future Outlook

6.5.4. Fresenius Kabi
6.5.4.1. Company Overview
6.5.4.2. Service Portfolio
6.5.4.3. Financial Information
6.5.4.4. Manufacturing Capabilities and Facilities
6.5.4.5. Recent Developments
6.5.4.6. Future Outlook

6.5.5. Glatt®
6.5.5.1. Company Overview
6.5.5.2. Service Portfolio
6.5.5.3. Manufacturing Capabilities and Facilities
6.5.5.4. Recent Developments
6.5.5.5. Future Outlook

6.5.6. Groupe SYNERLAB
6.5.6.1. Company Overview
6.5.6.2. Service Portfolio
6.5.6.3. Manufacturing Capabilities and Facilities
6.5.6.4. Future Outlook
6.5.7. Hovione
6.5.7.1. Company Overview
6.5.7.2. Service Portfolio
6.5.7.3. Manufacturing Capabilities and Facilities
6.5.7.4. Recent Developments
6.5.7.5. Future Outlook

6.5.8. Recipharm
6.5.8.1. Company Overview
6.5.8.2. Service Portfolio
6.5.8.3. Financial Information
6.5.8.4. Manufacturing Capabilities and Facilities
6.5.8.5. Recent Developments
6.5.8.6. Future Outlook

6.5.9. Siegfried
6.5.9.1. Company Overview
6.5.9.2. Service Portfolio
6.5.9.3. Financial Information
6.5.9.4. Manufacturing Capabilities and Facilities
6.5.9.5. Recent Developments
6.5.9.6. Future Outlook
6.6. Players in Asia-Pacific

6.6.1. CMIC Group
6.6.1.1. Company Overview
6.6.1.2. Service Portfolio
6.6.1.3. Financial Information
6.6.1.4. Manufacturing Capabilities and Facilities
6.6.1.5. Recent Developments
6.6.1.6. Future Outlook
6.6.2. Nectar Lifesciences
6.6.2.1. Company Overview
6.6.2.2. Service Portfolio
6.6.2.3. Financial Information
6.6.2.4. Manufacturing Capabilities and Facilities
6.6.2.5. Future Outlook

6.6.3. WuXi AppTec
6.6.3.1. Company Overview
6.6.3.2. Service Portfolio
6.6.3.3. Financial Information
6.6.3.4. Manufacturing Capabilities and Facilities
6.6.3.5. Recent Developments
6.6.3.6. Future Outlook

7. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
7.1. Chapter Overview
7.2. Small Molecules and Large Molecules Drugs / Therapies
7.2.1. Comparison of Key Characteristics
7.2.2. Comparison of Manufacturing Processes
7.2.3. Comparison of Key Manufacturing Challenges
7.3. Manufacturing of Large Molecules (Biologics): List of Biopharmaceutical CMOs

8. KEY INSIGHTS
8.1. Chapter Overview
8.2. Multipotentialite Service Providers: Heat Map Analysis
8.3. Pharmaceutical CMOs: Geographical Landscape
8.4. Pharmaceutical CMOs: Analysis by Geography, Company Size and Business Segment

9. CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Pharmaceutical Contract Manufacturing: Installed Global Capacity
9.3.1. Distribution by Size of CMOs
9.3.2. Distribution by Scale of Operation
9.3.3. Distribution by Location of Headquarters
9.3.4. Distribution by Location of Manufacturing Facilities
9.4. Concluding Remarks

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Pharmaceutical Contract Manufacturing Market, 2018-2028
10.3.1. Pharmaceutical Contract Manufacturing Market for API Manufacturing, 2018-2028
10.3.2. Pharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2018-2028
10.4. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions
10.4.1. Pharmaceutical Contract Manufacturing Market in North America, 2018-2028
10.4.1.1. Pharmaceutical Contract Manufacturing Market in the US, 2018-2028
10.4.1.2. Pharmaceutical Contract Manufacturing Market in Canada, 2018-2028
10.4.1.3. Pharmaceutical Contract Manufacturing Market in Mexico, 2018-2028
10.4.2. Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028
10.4.2.1. Pharmaceutical Contract Manufacturing Market in Italy, 2018-2028
10.4.2.2. Pharmaceutical Contract Manufacturing Market in Germany, 2018-2028
10.4.2.3. Pharmaceutical Contract Manufacturing Market in France, 2018-2028
10.4.2.4. Pharmaceutical Contract Manufacturing Market in Spain, 2018-2028
10.4.2.5. Pharmaceutical Contract Manufacturing Market in the UK, 2018-2028
10.4.2.6. Pharmaceutical Contract Manufacturing Market in Rest of Europe, 2018-2028
10.4.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028
10.4.3.1. Pharmaceutical Contract Manufacturing Market in India, 2018-2028
10.4.3.2. Pharmaceutical Contract Manufacturing Market in China, 2018-2028
10.4.3.3. Pharmaceutical Contract Manufacturing Market in Japan, 2018-2028
10.4.3.4. Pharmaceutical Contract Manufacturing Market in Australia, 2018-2028
10.4.3.5. Pharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2018-2028
10.4.4. Pharmaceutical Contract Manufacturing Market in Rest of the World, 2018-2028
10.4.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions
10.5. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product
10.6. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API
10.7. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF
10.7.1. Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028
10.7.2. Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028
10.7.3. Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028
10.8. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form
10.8.1. Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028
10.8.2. Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028
10.8.3. Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028
10.8.4. Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028
10.8.5. Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028
10.8.6. Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028
10.8.7. Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028
10.9. Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers
10.10 Concluding Remarks

11. SWOT ANALYSIS
11.1. Chapter Overview
11.2. Strengths
11.3. Weaknesses
11.4. Opportunities
11.5. Threats
11.6. Comparison of SWOT Factors

12. FUTURE OF THE PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12.1. Chapter Overview
12.2. Anticipated Growth in Outsourcing Activities
12.3. Growing Focus on Emerging Markets
12.4. Expansion of Capabilities and Emergence of One-Stop-Shops
12.5. Adoption of New Technologies and Focus on Innovation to Support Further Growth
12.6. Use of Big Data and Advanced Analytics to Improve Manufacturing Processes
12.7. Implementation of Cybersecurity Solutions to Safeguard Valuable Customer Data
12.8. Concluding Remarks

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Ajinomoto Althea
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Scott Goldstein, Associate Director, Drug Product Manufacturing

13.3. Bachem
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Thomas Fruh, Chief Executive Officer

13.4. Sovereign Pharma
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Piyush Desai, Director, Operations

13.5. Batavia Biosciences
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Claire Otjes, Assistant Marketing Manager

13.6. Polymun Scientific
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Dietmar Katinger, Chief Executive Officer

13.7. Rentschler Biopharma
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Birgit Schwab, Senior Manager Strategic Marketing

13.8. WACKER Biotech
13.8.1. Company Snapshot
13.8.2. Interview Transcript: Sebastian Schuck, Head of Business Development

13.9. CiVentiChem
13.9.1. Company Snapshot
13.9.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer

13.10. CordenPharma
13.10.1. Company Snapshot
13.10.2. Interview Transcript: Roberto Margartia, Business Development Director

13.11. Helsinn Group
13.11.1. Company Snapshot
13.11.2. Interview Transcript: Allison Vavala, Senior Manager, Business Development

13.12. Novasep
13.12.1. Company Snapshot
13.12.2. Interview Transcript: Kevin Daley, Market Director Pharmaceuticals

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Types of Manufacturers in Contract Manufacturing Industry
Figure 3.2 Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Range of Services Offered by CMOs
Figure 3.5 Factors for Selecting a CMO Partner
Figure 4.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 4.2 Pharmaceutical CMOs: Distribution by Geographical Location
Figure 4.3 Pharmaceutical CMOs: Regional Hubs
Figure 4.4 Pharmaceutical CMOs: Distribution by Company Size
Figure 4.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 4.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 4.7 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.8 Pharmaceutical CMOs: Distribution by Type of Service Offering
Figure 4.9 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Figure 4.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Figure 5.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 5.2 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Figure 5.3 Bubble Analysis: Regional Regulatory Summary
Figure 6.1 AMRI: Service Portfolio
Figure 6.2 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.3 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.4 Catalent® Pharma Solutions: Service Portfolio
Figure 6.5 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Figure 6.6 DPT® Laboratories: Service Portfolio
Figure 6.7 Patheon®: Service Portfolio
Figure 6.8 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Figure 6.9 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Figure 6.10 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Figure 6.11 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Figure 6.12 Aenova Group: Service Portfolio
Figure 6.13 Almac Group: Service Portfolio
Figure 6.14 CordenPharma: Service Portfolio
Figure 6.15 Fresenius Kabi: Service Portfolio
Figure 6.16 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Figure 6.17 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Figure 6.18 Glatt®: Service Portfolio
Figure 6.19 Groupe SYNERLAB: Service Portfolio
Figure 6.20 Hovione: Service Portfolio
Figure 6.21 Recipharm: Service Portfolio
Figure 6.22 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Figure 6.23 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Figure 6.24 Siegfried: Service Portfolio
Figure 6.25 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Figure 6.26 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Figure 6.27 CMIC Group: Service Portfolio
Figure 6.28 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Figure 6.29 Nectar Lifesciences: Service Portfolio
Figure 6.30 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Figure 6.31 WuXi AppTec: Service Portfolio
Figure 6.32 STA Pharmaceuticals (API Service Provider, WuXi AppTec): Service Portfolio
Figure 6.33 WuXi AppTec: Revenues (USD Million)
Figure 7.1 Small Molecules versus Large Molecules: Comparison of Key Characteristics
Figure 7.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Processes
Figure 7.3 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Figure 8.1 Multipotentialite Service Providers, Heat Map Analysis: Distribution by Geography, Company Size and Year of Establishment
Figure 8.2 Pharmaceutical CMOs: Geographical Landscape Analysis by Location of Manufacturing Facilities
Figure 8.3 Pharmaceutical CMOs: Distribution by Geography, Company Size and Business Segment
Figure 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Figure 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Figure 9.3 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Figure 9.4 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Figure 9.5 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 9.6 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 10.1 Pharmaceutical Contract Manufacturing: Market Forecast Approach
Figure 10.2 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Figure 10.3 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Figure 10.4 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.5 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.6 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Figure 10.7 Pharmaceutical Contract Manufacturing Market, 2018-2028: North America, Base Scenario (USD Billion)
Figure 10.8 Pharmaceutical Contract Manufacturing Market, 2018-2028: US, Base Scenario (USD Billion)
Figure 10.9 Pharmaceutical Contract Manufacturing Market, 2018-2028: Canada, Base Scenario (USD Billion)
Figure 10.10 Pharmaceutical Contract Manufacturing Market, 2018-2028: Mexico, Base Scenario (USD Billion)
Figure 10.11 Pharmaceutical Contract Manufacturing Market, 2018-2028: Europe, Base Scenario (USD Billion)
Figure 10.12 Pharmaceutical Contract Manufacturing Market, 2018-2028: Italy, Base Scenario (USD Billion)
Figure 10.13 Pharmaceutical Contract Manufacturing Market, 2018-2028: Germany, Base Scenario (USD Billion)
Figure 10.14 Pharmaceutical Contract Manufacturing Market, 2018-2028: France, Base Scenario (USD Billion)
Figure 10.15 Pharmaceutical Contract Manufacturing Market, 2018-2028: Spain, Base Scenario (USD Billion)
Figure 10.16 Pharmaceutical Contract Manufacturing Market, 2018-2028: UK, Base Scenario (USD Billion)
Figure 10.17 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Europe, Base Scenario (USD Billion)
Figure 10.18 Pharmaceutical Contract Manufacturing Market, 2018-2028: Asia-Pacific, Base Scenario (USD Billion)
Figure 10.19 Pharmaceutical Contract Manufacturing Market, 2018-2028: India, Base Scenario (USD Billion)
Figure 10.20 Pharmaceutical Contract Manufacturing Market, 2018-2028: China, Base Scenario (USD Billion)
Figure 10.21 Pharmaceutical Contract Manufacturing Market, 2018-2028: Japan, Base Scenario (USD Billion)
Figure 10.22 Pharmaceutical Contract Manufacturing Market, 2018-2028: Australia, Base Scenario (USD Billion)
Figure 10.23 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of Asia-Pacific, Base Scenario (USD Billion)
Figure 10.24 Pharmaceutical Contract Manufacturing Market, 2018-2028: Rest of the World, Base Scenario (USD Billion)
Figure 10.25 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Figure 10.26 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Figure 10.27 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Figure 10.28 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product and Regions, Base Scenario (USD Billion)
Figure 10.29 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Figure 10.30 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Figure 10.31 Pharmaceutical Contract Manufacturing Market for Solid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.32 Pharmaceutical Contract Manufacturing Market for Injectable Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.33 Pharmaceutical Contract Manufacturing Market for Semi-Solid / Liquid Form FDF, 2018-2028: Base Scenario (USD Billion)
Figure 10.34 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Figure 10.35 Pharmaceutical Contract Manufacturing Market for Tablets / Capsules / Blister Packing, 2018-2028: Base Scenario (USD Billion)
Figure 10.36 Pharmaceutical Contract Manufacturing Market for Glass / Plastic / Dropper Bottles, 2018-2028: Base Scenario (USD Billion)
Figure 10.37 Pharmaceutical Contract Manufacturing Market for Vials / Cartridges, 2018-2028: Base Scenario (USD Billion)
Figure 10.38 Pharmaceutical Contract Manufacturing Market for Ointments / Gels / Tubes, 2018-2028: Base Scenario (USD Billion)
Figure 10.39 Pharmaceutical Contract Manufacturing Market for Ampoules, 2018-2028: Base Scenario (USD Billion)
Figure 10.40 Pharmaceutical Contract Manufacturing Market for Sachets / Pouches / Bags, 2018-2028: Base Scenario (USD Billion)
Figure 10.41 Pharmaceutical Contract Manufacturing Market for Pre-filled Syringes, 2018-2028: Base Scenario (USD Billion)
Figure 10.42 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Figure 10.43 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)
Figure 11.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 11.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 11.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 11.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 11.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 11.6 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 12.1 Future of Pharmaceutical Contract Manufacturing Market
Figure 12.2 Emerging Markets in Pharmaceutical Contract Manufacturing Industry

List of Tables

Table 4.1 Pharmaceutical CMOs: List of Industry Players
Table 4.2 Pharmaceutical CMOs: Information on Type of FDF Offered
Table 4.3 Pharmaceutical CMOs: Information on Scale of Operation
Table 4.4 Pharmaceutical CMOs: Information on Type of Service Offering
Table 4.5 Pharmaceutical CMOs: Information on Location of Manufacturing Facilities
Table 4.6 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 5.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 5.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 6.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 6.2 AMRI: Manufacturing Facilities
Table 6.3 AMRI: Sterile Manufacturing Facilities
Table 6.4 AMRI: Recent Collaborations
Table 6.5 AMRI: Recent Expansions
Table 6.6 Catalent® Pharma Solutions: Manufacturing Facilities
Table 6.7 Catalent® Pharma Solutions: Recent Collaborations
Table 6.8 Catalent® Pharma Solutions: Recent Expansions
Table 6.9 DPT® Laboratories: Manufacturing Facilities
Table 6.10 DPT® Laboratories: Recent Collaborations
Table 6.11 DPT® Laboratories: Recent Expansions
Table 6.12 Patheon®: Manufacturing Facilities
Table 6.13 Patheon®: Recent Collaborations
Table 6.14 Patheon®: Recent Expansions
Table 6.15 Aenova Group: Manufacturing Facilities
Table 6.16 Aenova Group: Drug Product Manufacturing Capabilities
Table 6.17 Aenova Group: Recent Expansions
Table 6.18 Almac Group: Recent Collaborations
Table 6.19 Almac Group: Recent Expansions
Table 6.20 CordenPharma: Manufacturing Facilities
Table 6.21 CordenPharma: Recent Collaborations
Table 6.22 CordenPharma: Recent Expansions
Table 6.23 Fresenius Kabi: Manufacturing Facilities
Table 6.24 Fresenius Kabi: Packaging Capabilities
Table 6.25 Fresenius Kabi: Recent Collaborations
Table 6.26 Fresenius Kabi: Recent Expansions
Table 6.27 Glatt®: Manufacturing Facilities
Table 6.28 Glatt®: Recent Expansions
Table 6.29 Groupe SYNERLAB: Manufacturing Facilities
Table 6.30 Hovione: Manufacturing Facilities
Table 6.31 Hovione: Recent Collaborations
Table 6.32 Hovione: Recent Expansions
Table 6.33 Recipharm: Manufacturing Facilities
Table 6.34 Recipharm: Recent Collaborations
Table 6.35 Recipharm: Recent Expansions
Table 6.36 Siegfried: Manufacturing Facilities
Table 6.37 Siegfried: Recent Collaborations
Table 6.38 CMIC Group: Manufacturing Facilities
Table 6.39 CMIC Group: Recent Collaborations
Table 6.40 CMIC Group: Recent Expansions
Table 6.41 Nectar Lifesciences: Manufacturing Facilities
Table 6.42 WuXi AppTec: Manufacturing Facilities
Table 6.43 WuXi AppTec: Recent Collaborations
Table 6.44 WuXi AppTec: Recent Expansions
Table 7.1 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 7.2 List of Biopharmaceutical CMOs
Table 9.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 9.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Sovereign Pharma: Key Highlights
Table 13.4 Batavia Biosciences: Key Highlights
Table 13.5 Polymun Scientific: Key Highlights
Table 13.6 Rentschler Biopharma: Key Highlights
Table 13.7 WACKER Biotech: Key Highlights
Table 13.8 CiVentiChem: Key Highlights
Table 13.9 Helsinn Group: Key Highlights
Table 13.10 Novasep: Key Highlights
Table 14.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 14.2 Pharmaceutical CMOs: Distribution by Geographical Location
Table 14.3 Pharmaceutical CMOs: Distribution by Company Size
Table 14.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 14.5 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 14.6 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 14.7 Pharmaceutical CMOs: Distribution by Service Offerings
Table 14.8 Pharmaceutical CMOs: Distribution by Location of Manufacturing Facilities
Table 14.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Form Offered
Table 14.10 Regulatory Landscape for Pharmaceutical CMOs: Analysis by Type of Regulatory Authorities
Table 14.11 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 14.12 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 14.13 Catalent® Pharma Solutions: Annual Revenues, 2013-H1 2018 (USD Million)
Table 14.14 Thermo Fisher Scientific: Annual Revenues, 2013-2017 (USD Billion)
Table 14.15 Thermo Fisher Scientific: Revenues by Business Segments, 2017 (USD Billion)
Table 14.16 Patheon®: Annual Revenues, 2012-H1 2017 (USD Million)
Table 14.17 Patheon®: Revenues by Business Segments, 2016 (USD Million)
Table 14.18 Fresenius Kabi: Annual Revenues, 2013-2017 (EUR Million)
Table 14.19 Fresenius Kabi: Revenues by Product Segments, 2017 (EUR Million)
Table 14.20 Recipharm: Annual Revenues, 2013-2017 (SEK Million)
Table 14.21 Recipharm: Revenues by Business Segments, 2017 (SEK Million)
Table 14.22 Siegfried: Annual Revenues, 2013-2017 (CHF Million)
Table 14.23 Siegfried: Revenues by Product Segments, 2017 (CHF Million)
Table 14.24 CMIC Group: Annual Revenues, 2013-Q1 2018 (JPY Million)
Table 14.25 Nectar Lifesciences: Annual Revenues, 2012-Q3 2017 (INR Billion)
Table 14.26 WuXi AppTec: Revenues (USD Million)
Table 14.27 Approved Small Molecules and Large Molecules: Historical Trend (2005-2017)
Table 14.28 Pharmaceutical Contract Manufacturing Installed Capacity: Distribution by Size of CMOs (Sample Data Set)
Table 14.29 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 14.30 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Scale of Operation
Table 14.31 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Headquarters
Table 14.32 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 14.33 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 14.34 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Conservative Scenario (USD Billion)
Table 14.35 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Base Scenario (USD Billion)
Table 14.36 Overall Pharmaceutical Contract Manufacturing Market, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.37 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Base Scenario (USD Billion)
Table 14.39 Pharmaceutical Contract Manufacturing Market for API, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.40 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Conservative Scenario (USD Billion)
Table 14.41 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Base Scenario (USD Billion)
Table 14.42 Pharmaceutical Contract Manufacturing Market for FDF, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.43 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Conservative Scenario (USD Billion)
Table 14.44 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Base Scenario (USD Billion)
Table 14.45 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 14.46 Pharmaceutical Contract Manufacturing Market, Share by Regions, 2018, 2028 (Volume, %)
Table 14.47 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Conservative Scenario (USD Billion)
Table 14.48 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Base Scenario (USD Billion)
Table 14.49 Pharmaceutical Contract Manufacturing Market in North America, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.50 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Conservative Scenario (USD Billion)
Table 14.51 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Base Scenario (USD Billion)
Table 14.52 Pharmaceutical Contract Manufacturing Market in Europe, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.53 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Conservative Scenario (USD Billion)
Table 14.54 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Base Scenario (USD Billion)
Table 14.55 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2018-2028: Optimistic Scenario (USD Billion)
Table 14.56 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (USD Billion)
Table 14.57 Pharmaceutical Contract Manufacturing Market, 2018-2028: Market Attractiveness Analysis by Regions (Volume, % Share)
Table 14.58 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Conservative Scenario (USD Billion)
Table 14.59 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product, Base Scenario (USD Billion)
Table 14.60 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Types of API Product, Optimistic Scenario (USD Billion)
Table 14.61 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Conservative Scenario (USD Billion)
Table 14.62 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in North America, Base Scenario (USD Billion)
Table 14.63 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution of by Type of API Product in North America, Optimistic Scenario (USD Billion)
Table 14.64 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Conservative Scenario (USD Billion)
Table 14.65 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Base Scenario (USD Billion)
Table 14.66 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Europe, Optimistic Scenario (USD Billion)
Table 14.67 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Conservative Scenario (USD Billion)
Table 14.68 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Base Scenario (USD Billion)
Table 14.69 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Asia-Pacific, Optimistic Scenario (USD Billion)
Table 14.70 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Conservative Scenario (USD Billion)
Table 14.71 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Base Scenario (USD Billion)
Table 14.72 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of API Product in Rest of the World, Optimistic Scenario (USD Billion)
Table 14.73 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Conservative Scenario (USD Billion)
Table 14.74 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Base Scenario (USD Billion)
Table 14.75 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Scale of Production of API, Optimistic Scenario (USD Billion)
Table 14.76 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Conservative Scenario (USD Billion)
Table 14.77 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Base Scenario (USD Billion)
Table 14.78 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of FDF, Optimistic Scenario (USD Billion)
Table 14.79 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Conservative Scenario (USD Billion)
Table 14.80 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Base Scenario (USD Billion)
Table 14.81 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Type of Primary Packaging Form, Optimistic Scenario (USD Billion)
Table 14.82 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Conservative Scenario (USD Billion)
Table 14.83 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Base Scenario (USD Billion)
Table 14.84 Pharmaceutical Contract Manufacturing Market, 2018-2028: Distribution by Size of Manufacturers, Optimistic Scenario (USD Billion)
Table 14.85 Overall Pharmaceutical Contract Manufacturing Market: Comparative Evolution Scenarios, 2018 and 2028 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report:

3P Biopharmaceuticals
A&Z Pharmaceutical
A. S. Joshi & Company
Aalto Scientific
Aarti Industries
Abbott
AbbVie
ABL
Abzena
Accra Pac India
ACES Pharma
Acino International
ACS Dobfar
Actiza Pharmaceutical
Adar Biotech
Admac Formulations
Aenova
Aesica Pharmaceuticals
Affinity Life Sciences
Afton Scientific
Agno Pharma
AiPing Pharmaceutical
Air Water
Ajinomoto Althea
Ajinomoto OmniChem
Akorn
Akums Drugs & Pharmaceuticals
Al Bahja Group
Aland (Jiangsu) Nutraceutical
Albany Molecular Research (AMRI)
Albatros Pharmaceuticals
Albemarle
AlbyPharma
Alcami
Alcatel-Lucent
Aldevron
Alembic Pharmaceuticals
Alkermes®
AllChem Laboratories
Alliance Medical Products
Almac Pharma
Alpax Pharmaceutical
Alphora Research
Alps Pharmaceutical
Altaris Capital Partners
ALTHEA Pharma
Amanta Healthcare
Amatsigroup
Ambica Pharma Sales
AmbioPharm
AMEGA Biotech
American Antibiotics
Amgen®
Ami Lifescience
Amman Pharmaceutical Industries
Amneal Pharmaceuticals
Amoli Organics
AMPAC Fine Chemicals
Angelini
Anhui Biochem United Pharmaceutical
Ankur Drugs and Pharma
Anogen
Anqiu Lu'an Pharmaceutical
apceth Biopharma
Apex Pharmaceuticals
Apicore Pharmaceuticals
Apiscent Labs
APL
Apotex Fermentation
Aptuit
Arabio
Arbro Pharmaceuticals
Arch Pharmalabs
Arevipharma
Arran Chemical Company
Arvincare
Asahi Glass Company (AGC)
Asahi Kasei Finechem
Ashford Pharmaceutical Laboratories
Aspen Pharmacare Holdings
Aster Pharma
Asymchem Laboratories
ATRA Pharmaceuticals
AURA Biotechnologies
Aurelius
Aurobindo Pharma
Ausler Snovy Healthcare
AustarPharma
Austin Pharmaceuticals
AutekBio
Avecia
Avid Bioservices
Avra Laboratories
Avyukt Pharmaceuticals
Axa Parenterals
Baccinex
Bachem
Bal Pharma
Batavia Biosciences
Bausch & Lomb
Baxil Pharma
Baxter BioPharma Solutions
Bayer
BCN Peptides
Beach Products
Becton Dickinson
Beijing Second Pharmaceutical
Belcher Pharmaceuticals
Belco Pharma
Beltapharm
Bennet Pharmaceuticals
BePharBel
Beximco Pharmaceuticals
Bharat Pharmaceuticals
Bharat Serums and Vaccines
BIBITEC
BINEX
Bio Elpida
BioCell
BioClin Laboratories
Biocon
BioConnection
BIOFABRI
Bio-Garten
Biogen
Biological E
BioMARC
Biomatik
Biomay
BIOMEVA
Bio-Pharm
BioPharmaceuticals Australia
Bioserv
BioSynergy
Bio-Synthesis
Biotech Vision Care
BioTechLogic
BioTechnique™
Biotechpharma
Biovectra
Biovian
Bluepharma
Blueprint Medicines
Boehringer Ingelheim BioXcellence
Bonarum Pharma
Brammer Bio
Brassica Pharma
Brazilian Health Regulatory Agency (ANVISA)
Broad Institute of MIT and Harvard
Broad Pharmaceutical
Bruker Daltonics
Bruschettini
Bryllan
BSP Pharmaceuticals
C & O Pharmaceutical Technology
Cadila Pharmaceuticals
Calyx Chemicals & Pharmaceuticals
Cambrex
Capgemini
Caplin Point Laboratories
Capsugel®
CARBOGEN AMCIS
Catalent® Pharma Solutions
Cayman Chemical
Cell and Gene Therapy Catapult
Cell Culture Company
Cell Essentials
Cell Therapies
CELLforCURE
Cellin Technologies
Celltech
Celltrion
Cellular Therapeutics
Celonic
Cenexi
Centaur Pharmaceuticals
Center for Biocatalysis and Bioprocessing, The University of Iowa
Central Drugs Standard Control Organization (CDSCO)
Century Pharmaceuticals
CEPiA Sanofi
Cerbios-Pharma
CF Pharma
Charles River Laboratories
Chartwell Pharmaceuticals
ChemCon
Chemi Peptides
Chemigran
ChemPacific
ChemPartner
Cherokee Pharma
Chifeng Arker Pharmaceutical Technology
China Chemical & Pharmaceutical (CCPC)
China Food and Drug Administration (CFDA)
Chiral Biosciences
Chirogate International
Chongqing Huapont Pharmaceutical
Chromo Laboratories
Chunghwa Chemical Synthesis & Biotech
CinnaGen
Ciron Group
Cirrus Pharmaceuticals
CiVentiChem
Clinical Trial Consultants (CTC)
Cloud Holdings
CMC Biologics
CMC Milling
CMIC Group
Coating Place
Cobra Biologics
COC Farmaceutici
Cody Laboratories
Cognate BioServices
Columbia University
Combino Pharm
Comprehend Systems
Concord Biotech
Concord Drugs
Confab Laboratories
Contract Coating
Contract Pharmacal
Cook Pharmica
Corden BioChem
CordenPharma
CoreRx®
CP Pharmaceuticals
Creative® Biolabs
CRELUX
Cris Pharma
Crown Laboratories
CTX Lifesciences
Custom Pharmaceuticals
Cyalume® Speciality Products
Cytovance® Biologics
Daiichi Sankyo
Daito Pharmaceutical
Dalton Pharma Services
Delavau Pharmaceutical Partners
Delmar Chemicals
Delpharm
Delta Laboratories
Dermopartners
DEVA Holding
DFB Pharmaceuticals
Dhruv Life Sciences
Dipharma Francis
Dishman Group
Divis Laboratories
DM Pharma
dmBio
DOTTIKON EXCLUSIVE SYNTHESIS
Douglas Pharmaceuticals
DPT® Laboratories
Dr. Reddy's Custom Pharmaceutical Services (CPS)
Dupen Laboratories
Dwarkesh Pharmaceuticals
Eagle Pharmaceuticals
Eden Healthcare
Ei-A Pharmaceutical SolutionWorks™
EirGen Pharma
EirGenix
EL Laboratories
Elite Pharmaceuticals
Elli Lilly
Embio
Emcure Pharmaceuticals
Emergent Biosolutions®
Eminent Healthcare
Enaltec Labs
Encap Drug Delivery
Enrich Pharma
Entema Laboratorios
Entod Pharmaceuticals
Epic Pharma
EPTEK Technology
Ercros
Eriochem
Erregierre
Esteve Química
Ethypharm
EuBiologics
EUCODIS Bioscience
EUFETS
Eurogentec
Euro-Med Laboratories
European Medicines Agency (EMA)
Euticals
Evonik Industries
Evotec
Excella
Exela Pharma Sciences
Exostar
Exova SL Pharma Labs
F. I. S. Fabbrica Italiana Sintetici
Famar
Famy Care
Fareva®
Farmabios®
Farmak
Farmhispania Group
Farmigea
FDC
Fermion
Ferndale Laboratories
Finecure Pharmaceuticals
FineTech Pharmaceuticals
Flamingo Pharmaceuticals
Flamma
Fleming Laboratories
Fluid Energy Processing and Equipment
Fresenius Kabi
Fresenius Kabi Product Partnering
FUJIFILM Diosynth Biotechnologies
Fujimoto Chemicals
Fusion Antibodies
Future Pak
G&W Laboratories
Gadea Pharmaceutical Group
Gala Biotech
Galentic Pharma
Gattefossé
GD Pharma
GE Healthcare
Gedeon Richter
Gemini PharmChem Mannheim
Gene Transfer Vector Core (GTVC)
GeneCure Biotechnologies
Genentech
GenIbet Biopharmaceuticals
Gerresheimer
Getz Pharma Research
Gland Pharma
Glatt®
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Global Pharmatech
Glochem Industries
Glycotope Biotechnology
GNH India
goBalto
Goodwin Biotechnology
GP Pharm
Grand River Aseptic Manufacturing
Granules India
Granules Omnichem
GreenPak Biotech
Grindeks
Groupe PARIMA
Groupe SYNERLAB
Grupo Farmasierra
GTCR
GTP Technology
Guardian Drug Company
Hainan Poly Pharm
Hainan Visum Pharmaceutical
HALIX
Halo Pharma
Handok
Hanford Pharmaceuticals
Hangzhou Hysen Pharma
Hangzhou Imaginechem
Hangzhou Panyu Chemical
Hanuchem Laboratories
HD Biosciences
Health Biotech
Health Canada
Healthcare Pharmaceuticals
Healthy Life Pharma
Helios Pharmaceuticals
Helsinn Group
Hetero Drugs
Hewlett-Packard®
HighRes Biosolutions
Hikal
Hikma Pharmaceuticals
Histocell
hollomet®
Hong Kong Institute of Biotechnology
Honson Pharmatech Group
Horizon Pharma
Hospira One2One
Hovione
Howard Hughes Medical Institute (HHMI)
Hritik Chemicals
Hubei Biocause Pharmaceutical
IBM®
Icagen
ICROM
IDT Australia
IDT Biologika
Illumina
Indena
Indian Immunologicals
Indoco Remedies
Ind-Swift Laboratories
Ingenus Pharmaceuticals
Inke
Inno Biologics
Innova Captab
Institute for Advanced Study (IAS)
INSYS Therapeutics
Intas Pharmaceuticals
Integrity Bio
International Chemical Investors Group (ICIG)
International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
Interquim
Invent Farma
inVentiv Health
IPC Process-Center
i-Pharmaceuticals
Istituto Biochimico Italiano Giovanni Lorenzini
IVAX Pharmaceuticals
J. B Chemicals & Pharmaceuticals
Janssen Pharmaceuticals
Japan CMO Association (JCMOA)
JGL
JHL Biotech
Johnson & Johnson
Johnson Matthey
JSC Olainfarm
Jubilant Life Sciences
Julphar Gulf Pharmaceutical Industries
Juno Therapeutics
JW Biotechnology
Jyoti Capsulations
KABS Pharmaceutical Services
Kamat Pharmatech
Kancera
Karolinska University Hospital
Katsura Chemical
KBI Biopharma
Kekule Pharma
Kemwell Biopharma
Keryx Biopharmaceuticals
Kilitch Healthcare
Kongo Chemical
Korten
KP Pharmaceutical Technology
Krebs Biochemicals & Industries
KRS Global Biotechnology
Kyowa Pharma Chemical
Laboratório Edol
Laboratorios Farmacéuticos ROVI
Laboratorios Lesvi
Laboratorios SALVAT
Laccure
Lameplast Group
LAMPIRE Biological Laboratories
Lannett
Laurus Labs
Lenovo™
Lenus LifeCare
LFB BIOMANUFACTURING
LIDDS™
Life Sciences Solutions
Life Technologies™
Lifekyor Pharmaceuticals
Lloyd Laboratories
LOBA Feinchemie
Logos Pharma
Lomapharm®
Long Pharmaceuticals
Lonza
LSNE Contract Manufacturing
Luina Bio
Luitpold Pharmaceuticals
Lyne Laboratories
MabPlex
MacFarlan Smith
Macter International
Madras Pharmaceuticals
Maine Biotechnology Services
MAKCUR Laboratories
Malik Lifesciences
Malladi Drugs & Pharmaceuticals
Manav Drugs
Marchesini Group
Marksans Pharma
Massachusetts Institute of Technology
MassBiologics
MaSTherCell
Maxcure Nutravedics
Maya Biotech
Mayne Pharma Group
McGuff Pharmaceuticals
MDC Pharmaceuticals
Meda Pharmaceuticals
Medical Products Laboratories
Medichem
Medicines and Healthcare products Regulatory Agency (MHRA)
Medicines Control Council (MCC)
Medilux Laboratories
Mediwin Pharmaceuticals
Medix Biochemica
MedPharm
Menadiona
Menarini Biotech
Mercator Pharmaceutical Solutions
Merck
Meridian Life Science
Meridian Medicare
Merro Pharmaceutical
Metrics Contract Services
Metrochem API
Micro Labs
MicroBiopharm Japan
Micro-Sphere
Mikart
Ministry of Food and Drug Safety (MFDS)
Ministry of Health, Labour and Welfare (MHLW)
Mipharm
Mitim
MSN Laboratories
Multi-Pack Solutions
Murty Pharmaceuticals
Mycenax Biotech
Mylan®
Nakoda Chemicals
Nanjing Pharmatechs
NATCO Pharma
National Center for Advancing Translational Sciences
National Institutes of Health
Nectar Lifesciences
NEISS Labs
Nephron Pharmaceuticals
NerPharMa
Neuland Laboratories
New York Center for Nanomedicine Research
Nexgen Pharma
Nextar Chempharma Solutions
Nimbles Biotech
Ningbo Renjian Pharmaceutical Group
Nippon Rika Technologies
Nipro Patch
Nitin Lifesciences
Nitto Avecia Pharma Services
Nitto Denko Avecia
Nivon Specialties
Norac Pharma
North Star Processing
Norwegian Institute of Public Health
Norwich Pharma Services
Nova Laboratories
NovaMed Pharmaceuticals
Novartis
Novasep
Novel Laboratories
Novex Innovations
Nutragen Pharma
NutraLab
NVRON Life Science
Oakwood Laboratories
Oasis Laboratories
Oceanic Pharmachem
OctoPlus
Olon
Oman Pharmaceutical Products
Omnia Biologics
Onco Generics
Oncotec Pharma Produktion
OPKO Health
Optel Vision
Orchid Pharma
Orient EuroPharma
Orient Pharma
Orion
Orofino Pharmaceuticals Group
Oso BioPharmaceuticals Manufacturing
Oxford BioMedica
P&R Holding
Pan American Health Organization (PAHO)
Panacea Biotec
PannonPharma
Parabolic Drugs
Paragon® Bioservices
Particle Sciences
Patheon®
PB-L Productos Bio-Lógicos
PCI Synthesis
PCT Cell Therapy
Pegasus Farmaco India
Penn United Industries
Perrigo®
Pfizer
Pfizer CentreOne
Pharma Stulln
PharmaCell
Pharmaceutical Associates
Pharmaceutical Manufacturing Research Services (PMRS)
Pharmaceutical Medical Devices Agency (PMDA)
Pharmaceutics International (Pii)
Pharmacia & Upjohn
PharmAgra Labs
Pharma-Q
Pharmascience
Pharmasol
Pharmatronic
PharmaZell
Pharmedartis
Pharmer
Pharmicell
Phenom-World
Phytex Australia
Phyton Biotech
Pierre Fabre
Pillar5 Pharma
Pinewood Healthcare
Piramal Pharma Solutions
PiSA Farmaceutica
Pisgah Laboratories
PlasmidFactory
PMC Isochem
Polpharma
Polymun Scientific
PolyPeptide Group
Polysciences
Porton Fine Chemicals
Praxis Pharmaceutical
Precision Antibody
Preet Remedies Group
PREMAS Biotech
Prima BioMed
PrimaPharma
Prisha Healthcare
ProBioGen
Procaps
Procos
Profectus BioSciences
ProJect Pharmaceutics
ProMab Biotechnologies
Proton Pharma
Provizer Pharma
PRWT Services
PT. ETHICA Industri Farmasi
Pure & Cure Healthcare
PX'Therapeutics
Pyramid Laboratories
QS Pharma
Qualigen
Qualiphar-Gifrer
Qualitron Bio Medica
Quality Chemical Laboratories
Qualtra Pharmaceuticals
Quay Pharma
Que Pharma
Radico Remedies
Rafarm
Ramsey Design Group
Rank Group
Recipharm
Redwing Pharma
Regis Technologies
Reliable Biopharmaceutical®
Reliance Life Sciences
Remington Pharmaceuticals
Renaissance Acquisition Holdings
Rentschler Biopharma
ResearchPoint Global
Richter-Helm BioLogics
RiconPharma
RIVOPHARM
RL Fine Chem
Robert Wood Johnson Medical School
Roche
Rommelag
Rompharm
Roslin Cell Therapies
Rottendorf Pharma
Rubicon Research
Rusan Pharma
SAFC Pharma™
SAI Life Sciences
Salvus Pharma
Sandoz
Sanico
SANOCHEMIA Pharmazeutika
Sanquin Pharmaceutical Services
Sanwa Kagaku Kenkyusho
Sarvodaya Drugs & Pharmaceuticals
Sarvotham Care
Sato Pharmaceutical
SAVA Healthcare
Savior Lifetec
Schering-Plough
SCI Pharmtech
Scientific Protein Laboratories
ScinoPharm
SEA Vision
Seacross Pharmaceuticals
Sekisui Medical
Selvok Pharmaceutical
Senn Chemicals
Sensilab®
Sentiss Pharma
Sesderma Group
Shandong Xinhua Pharmaceutical
Shanghai Pharmaceuticals Holding
Shanghai Shyndec Pharmaceutical
Sharon Bio-Medicine
Shasun Pharmaceuticals
Shilpa Medicare
Shionogi
Shire
Sichuan Huiyu Pharmaceutical
Siegfried
Sigmapharm Laboratories
SignaGen Laboratories
Singota Solutions
Sinopharm
Sirio Pharma
SM Pharmaceuticals
Smruthi Organics
SMS Pharmaceuticals
Societa Italiana Medicinali Scandicci
Softgel Healthcare
Softigel
SOHO Global Health
Solitaire Pharmacia
Sovereign Pharma
Square Pharmaceuticals
Sricure Herbs
ST Pharm
STA Pharmaceutical
STADA Arzneimittel
Stason Pharmaceuticals
Stericon
Steril-Gene Life Sciences
Strides Shasun
Sunrise International Labs
Sunrise Pharma
Sunways
Suven Life Sciences
Suzuken
Swiss Pharma
Symbiosis Pharmaceutical Services
Symed Labs
Synbias Pharma
SynCo Bio Partners
Syncom Healthcare
Syngene International
SYNLAB Group
Syntech Pharmachem
Synthokem Labs
Syntonix Biofarm
Tahira Industries India
Tai Heng Industry
Takara Bio
Tara Innovations
Tedor Pharma
Teligent
TESARO
Teva Active Pharmaceutical Ingredients (TAPI)
The Carlyle Group
The Native Antigen Company
The Ritedose
Theon Pharmaceuticals
Therapeutic Goods Administration (TGA)
Therapure Biopharma
Thermo Fisher Scientific
Tianjin Pharmaceutical Group
Tillotts Pharma
Time-Cap Labs
Titan Pharma
TOLMAR
Tonus-Les
Torrent Pharmaceuticals
Toyobo Biologics
TraceLink
TranXenoGen
trenzyme
Tubilux Pharma
Tyger Scientific
Ultra Tab Laboratories
Ultratech India
Unibiotech Formulations
Unichem Laboratories
Unimark Remedies
Union Quimico Farmaceutica (UQUIFA)
Unison Chemical Works
United States Food and Drug Administration (USFDA)
University of Alabama
University of Minnesota
University of Nebraska
University of Newcastle
University of Pennsylvania
University of Utah
UPM Pharmaceuticals
Uppsala University Hospital
URSAPHARM Arzneimittel
US Pharma Lab
USV
Valeant Pharmaceuticals International
Veeva Systems
Vendiz Pharmaceuticals
VerGo Pharma Research
Vertex Pharmaceuticals
Vetter Pharma
VGXI
Vibalogics
Vigene Biosciences
Virbac
Virovek
Vista Biologicals
Vital Health Care
Vivimed Labs
VUAB Pharma
WACKER Biotech
Waisman Biomanufacturing
Wanbury
WellSpring Pharmaceutical
West Pharmaceutical Services
WeylChem Group
Wilmington PharmaTech
Windlas Healthcare
Wintac
Wisdom Pharmaceutical
Wockhardt
World Health Organization (WHO)
World Intellectual Property Organization (WIPO)
World Trade Organization (WTO)
Wuhan Biocause Pharmaceutical Development
WuXi AppTec
WuXi NextCODE
Xellia Pharmaceuticals
Xi'an Lijun Pharmaceutical
XtalPi
Xttrium Laboratories
YaoPharma
Yash Pharma Laboratories
Yung Zip Chemical
Zach System
Zambon
Zenacts Pharma
Zenara Pharma
Zenith Healthcare
ZenLabs Ethica
ZheJiang Apeloa JiaYuan Pharmaceutical
Zhejiang Changming Pharmaceutical
Zhejiang Cheng Yi Pharmaceutical
Zhejiang Excel Pharmaceutical
Zhejiang Hisun Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhejiang Huangyan Fine Chemical Group
Zhejiang Jingxin Pharmaceutical
Zydus BSV Pharma
Zydus Cadila

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

Site License USD 7,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Enterprise License

USD 14,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

Example Insights

Overview

Contents

Table of Contents

List of Figures

List of Tables

Listed Companies

Segmentation

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 3,499

Site License USD 7,999

OUR CLIENTS

YOU MAY ALSO LIKE

Mitochondrial Disease Therapies: Unlocking Treatment for Orphan Diseases

Abuse Deterrent Formulation Technologies: Combating Prescription Drug Abuse

License	Price
Single-User License This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print multiple copies, solely for your use. Under this agreement, the report (either full or in part) should not be redistributed or reproduced in any form. Unless a Site License or an Enterprise License is purchased, a Single User license must be purchased for every person that wishes to use the report within the same enterprise.	USD 3,499
Site License This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple copies for use by employees at the same location. Apart from this, the report (either full or in part) should not be redistributed or reproduced in any form. It is the buyer’s responsibility to ensure that the report is kept secure and isn’t made available to any third party.	USD 7,999
Enterprise License This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the maximum number of prints which can be taken. However, it is the buyer’s responsibility to ensure that the report is kept secure and isn’t made available to any third party.	USD 14,999

LOGIN

Forgot Password

Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

Example Insights

Overview

Contents

Table of Contents

List of Figures

List of Tables

Listed Companies

Segmentation

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 3,499

Site License USD 7,999

OUR CLIENTS

YOU MAY ALSO LIKE

Stem Cell Therapy Contract Manufacturing Market, 2019-2030

Vaccine Contract Manufacturing Market (2nd Edition), 2019-2030

Natural Killer Cell Therapies: Pipeline Review

SUBSCRIBE TO INDUSTRY UPDATES

Mitochondrial Disease Therapies: Unlocking Treatment for Orphan Diseases

Abuse Deterrent Formulation Technologies: Combating Prescription Drug Abuse